Skip to main content
U.S. flag

An official website of the United States government

Data Sharing: Access to clinical trial data/samples (Milestone 3.D)

In Progress

Timeline Start - End

2018 - 2025

Research Implementation Area

Data Sharing and Reproducibility

Enable access to data and associated biosamples and biomarkers from completed, ongoing, and future federally and privately funded clinical trials to clarify the biomarkers’ predictive and theragnostic value, to identify surrogate endpoints, and to advance the understanding of heterogeneity of disease and treatment response.

Success Criteria

  • Provide support to enhance completed and ongoing clinical trials with molecular profiling of minimally invasive specimens (serum, peripheral monocytes, microbiome etc.) and use these molecular signatures as indicators of responsiveness and for disease sub-classification.

  • Develop standard consenting language, simplified data, and material transfer agreements, and provide support for big data infrastructure to ensure the rapid, widespread and appropriate, use/reuse of data and biosamples.

  • Align funding incentives across federal and non-federal/private trial sponsors to ensure rapid and broad access to data and associated biosamples and biomarkers from legacy, ongoing and future clinical trials.

Summary of Key Accomplishments

NIA’s Clinical Trials program is implementing a policy that requires the timely sharing of data and biosamples from all NIA-funded, early- and late-stage trials, including registration trials. The sharing of data and biosamples from the A4 Study has led to new insights related to differences in the presence of AD biomarkers among participants from different ethnic and racial groups.

The NIA-supported National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) hosts biosamples from clinical research studies and provides access to these biological materials to qualified researchers for use in a wide array of research projects.

NIA’s Drug Repurposing funding initiative encourages research that utilizes peripheral fluids biosamples from ongoing, as well as legacy, clinical trials to generate genomic data that can be used to understand the determinants of responsiveness to treatment.

The key accomplishments summary is current as of July 2022. 

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations

Related Milestones

Search all Research Categories

An official website of the National Institutes of Health